Academia.edu no longer supports Internet Explorer.
To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser.
2010, The Cambridge Law Journal
…
3 pages
1 file
AI-generated Abstract
The paper critiques the application of EU competition law, particularly in the context of market integration objectives. It discusses the GlaxoSmithKline case, highlighting the tension between traditional interpretations of competition law and a more economically-focused approach aimed at consumer welfare. The work argues for a reevaluation of the objectives of competition law and its effectiveness in ensuring market integration.
Parallel trade traditionally enjoys a significant protection from European Institutions, in the belief that it fosters competition and encourages trade. However, pharmaceutical companies claim that this form of competition undermines their incentive to innovate and threatens the competitiveness of the European pharmaceutical sector. This Article analyses a) the arguments put forward in favour of and against the freedom of the parallel trade of pharmaceuticals between the EU Member States and b) the case-law relating to the parallel trade of pharmaceuticals developed by the EU courts and, more specifically, by the Court of Justice (“CJ”) (former Court of Justice of the European Communities/“ECJ”) and by the General Court (“GC”) (former Court of First Instance of the European Communities/“CFI”) in the light of EU competition law (Arts 101–102 of the TFEU).
Misión Jurídica, 2020
The theme of the present article is to deliver the notion that in order to enforce competition rules which, are aimed at maintaining a balance between profitability of the competitors and welfare of the consumers, the crucial aspect in attainting it is a healthy competitive market. Therefore, an attempt is made to analyses the role and practice of the European Courts and the Commission in protecting the structure of the competitive market as a means to secure the interests of the consumers and competitors. To convey the notion of the paper, sustenance from one of the imperative decisions given by the European Court of Justice purporting the predominant idea has been taken from the case of GlaxoSmithKline v Commission and other relevant cases from the locales of Article 101 coupled with Article 102 of the Treaty on the Functioning of the European Union. The idea is to critically discuss the rationale of the decision delivered by the hierarchy of courts, the object-effect dichotomy under Article 101(1) for apprehending anti- competitive conduct, and to reflect upon the Commission guidelines.
SSRN Electronic Journal, 2013
The European Union protects parallel trade as one of the foundations of the Union. Although the pharmaceutical sector is more sensitive to parallel trade, no distinction is made for this specific industry. Thus, this thesis tries to cover parallel trade issues in pharmaceutical industry and assess whether there is room for justified restrictions of parallel trade within EU competition rules.
2017
The XII Conference of Treviso on “Antitrust between EU law and National law” was a forum for debate on the main current antitrust issues, which were examined from a variety of points of view and relating to the most diverse sectors of the economy. In this context, antitrust law did not fail to show its vitality, brought to the limelight by the numerous participants coming from many parts of the world and strongly interested in this subject matter.
European Competition Journal, 2011
Journal of Consumer Policy, 2010
The European Commission (EC) and the European Courts have being reaffirming in the Deutsche Telekom and Telefónica cases that guide-prices established by sector regulators upon electronic communications incumbents cannot per se exclude that conducts with anticompetitive foreclosure effects, such as margin squeeze, undertaken within the boundaries of those pre-established prices, can be considered abusive under Article 102 TFEU. The paper aims at showing that the reasoning put forward by the EC and the Courts not only dismantles the defensive reasoning put forward by the incumbents before the EC and on appeal before the Courts but actually reaffirms the centrality of the enforcement activity of the EC. The paper examines the reasoning behind the “regulatory authority’s instructions defence” – the argument of the incumbents stating that their actions were justified because they had set their wholesale access prices and retail prices in line with the guidelines imposed by the sectorial regulators. Recalled in this context were also the principles of proportionality, subsidiarity and fair cooperation between the EC and individual Member States. The affirmation of the “heliocentric” doctrine that puts the EC at the hearth of competition law enforcement vis á vis national regulators and domestic legislation (provided decisions of the regulatory authorities can be considered secondary law sources) should take into consideration the important precedent of Consorzio Industrie Fiammiferi. The latter affirms that competition authorities can automatically put aside legislation that goes against Article 101 TFEU. However, they cannot impose pecuniary fines when certain behaviours are imposed by national legislation (while they can impose fines if those behaviours were suggested or facilitated by national legislation).
European Competition Law Review, 2018
Journal of Antitrust Enforecement, 2024
This article investigates the evolution of the European Union (EU) competition law and policy enforcement in the pharmaceuticals sector, focusing on the impact of the coronavirus disease 2019 (COVID-19) crisis as a turning point. Before COVID-19, EU competition authorities' goals and priorities focused on pay-for-delay agreements between originators and generic pharmaceutical undertakings. During COVID-19, the European Commission developed soft laws (such as temporary frameworks and comfort letters) enabling undertakings to cooperate to increase access to essential health products and COVID-19 vaccines. In the post-pandemic era, initiatives like the Pharmaceutical Strategy for Europe, the Single Market Emergency Instrument (SMEI), the Health Emergency Response Authority (HERA), the compulsory licensing proposal and the upcoming changes in the pharmaceutical regulations reflect a patient-centred approach and diverse agenda. This article underscores the move towards a more inclusive EU competition law and policy framework in the pharmaceutical sector as part of this evolution.
Scripta Theologica, 2022
1.ª edición Anestesiología Manual CTO de Medicina y Cirugía, 2020
World Journal of Advanced Research and Reviews, 2024
Studi Pengembangan Smart Grid di Indonesia, 2024
The Annual of the British School at Athens, 2002
Sistematización de experiencias: Vivencias de extensión universitaria crítica, 2024
Physiology & Behavior, 2021
Verso & Reverso, 2004
Revista de ALAIC, 2011
Cadernos de Pesquisa
Phytochemical analysis : PCA, 2016
Journal of the Brazilian Society of Mechanical Sciences and Engineering, 2020
Microorganisms, 2022
International Journal of Modern Physics D, 2018
European Journal of Applied Physiology, 2004